A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

To join this study, you must be an adult aged 18 or older. You will need to have been diagnosed with multiple myeloma that has either returned or not responded to previous treatments, and you must have received treatment with lenalidomide before. Your doctors will also need to be able to measure your cancer, meaning there are clear signs of the disease that they can track.

Also, your body needs to be working well enough to handle the treatment, and you should be generally able to carry out your daily activities without too much difficulty. The research team will do some tests to make sure you meet all these health requirements.

You cannot join if your multiple myeloma has spread to your brain or spinal cord, or if your cancer is so aggressive that you need immediate treatment. Also, if you only have a single growth of cancer cells (a solitary plasmacytoma) or non-secretory myeloma without other measurable signs of disease, you might not be able to take part.

If you decide to join this study, you will receive either the new drug, BMS-986393, or a standard treatment for multiple myeloma. The specific schedule for your medication and any doctor's visits, tests, and scans will be clearly explained by the study team. You will have regular appointments where doctors will check how you are responding to treatment and monitor for any side effects.

These visits will involve blood tests, physical exams, and other medical assessments to track your health and the progress of your multiple myeloma. The total length of your participation will vary, but it includes the treatment period and then a follow-up period where doctors will continue to monitor your health, even after you stop taking the study medication.